We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

MXC Mgc Pharmaceuticals Limited

-0.0025 (-3.23%)
04 Oct 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Share Name Share Symbol Market Type Share ISIN Share Description
Mgc Pharmaceuticals Limited LSE:MXC London Ordinary Share AU000000MXC6 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0025 -3.23% 0.075 0.07 0.08 0.0775 0.07 0.07 3,377,400 08:26:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Drug & Proprietary Stores 4.3 -20.8 -0.6 - 3.32

Mgc Pharmaceuticals Share Discussion Threads

Showing 17076 to 17089 of 17525 messages
Chat Pages: Latest  689  688  687  686  685  684  683  682  681  680  679  678  Older

01/03/2023 7:02am
UK Regulatory (RNS & others)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart

From Feb 2023 to Mar 2023

Click Here for more Mgc Pharmaceuticals Charts.

RNS Number : 4761R

MGC Pharmaceuticals Limited

01 March 2023

MGC Pharmaceuticals Ltd.

Appointment of UK Lead Broker and Change of Company Secretary

01 March 2023


MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to announce the appointment of UK based Peterhouse Capital as the Company's lead broker on the LSE, with immediate effect, replacing Turner Pope. This appointment is part of the Company's UK focused corporate strategy with respect to future equity capital market financings and corporate opportunities.

MGC Pharma's non-executive chairman, Mr Brett Mitchell, commented "The board is very pleased to welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the company's future funding strategies and corporate opportunities. In addition, we would also like to thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him every success with his next venture."


the mugger
Beware forward selling. Look at the many previous rns, another one is due in 2 weeks

MGC Pharmaceuticals Limited US$10m Financing Agreement with Mercer Street
29/07/2022 7:00am
UK Regulatory (RNS & others)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart

From Mar 2022 to Mar 2023

Click Here for more Mgc Pharmaceuticals Charts.

RNS Number : 2251U

MGC Pharmaceuticals Limited

29 July 2022

MGC Pharmaceuticals Ltd.

New US$10m Financing Agreement signed with US-based Strategic Fund and Largest Shareholder, Mercer Street Capital

29 July 2022


MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce that it has entered into a new convertible securities financing agreement (Financing Agreement) with Mercer Street Global Opportunity Fund, LLC, a fund managed by Mercer Street Capital Partners, LLC, a United States-based institutional fund manager (together, "Mercer") and MGC Pharma's largest shareholder, to provide the Company with a substantial funding facility of up to a total of US$10m. This fully funds the current MGC Pharma business plan and replaces the unused amount of the convertible facility announced in September 2020[1] , providing MGC with material financing facility to be drawn on as required to execute its strategy.

The first tranche of US$1.20 million will be provided to the Company upon satisfaction of the closing conditions (including lodging a cleansing statement), through the issue of 1.32M convertible notes with a face value of US$1 each to Mercer Street ( Tranche 1 Notes ).

This US$10m financing facility provides MGC Pharma with access to significant capital in order to execute its business commercialisation strategy primarily, with Sciensus Rare in the UK and EU and AMC in the USA, as well as advance the regulatory approvals for the Company's proprietary products to drive revenues, assist in the rollout of the ZAM App and provide funding for the Group's general corporate expenses. The Company will continue implement significant non revenue driving cost controls, as announced in it recent June Quarter Activities Report, within the operations including the delay of non-core clinical trials, and will look to use funding under this agreement selectively to support new growth and strategic initiatives.

Key Terms

The key terms of the Financing Agreement are set out below:

-- Convertible Securities facility of up to $US10m in total.
-- The initial tranche of convertible securities issued will provide funding of US$1.2m to MGC Pharma. In addition, the company will issue 21,511,545 fully paid ordinary shares to Mercer in consideration for the provision of funding. Both issues will be made utilising MGC Pharma's existing capacity.

-- Subsequent tranches of funding are available up to a value of US$8.8m within 18 months of execution of the agreement, with access to the additional funding subject to normal conditions precedent for a facility of this nature including MGC Pharma having sufficient capacity under Chapter 7 of the Listing Rules to issue the convertible notes or shareholder approval being obtained.

-- For each US$1.00 of funding provided to MGC Pharma, the Company will issue Mercer Convertible Securities to the value of US$1.10.

-- The value of outstanding Convertible Securities held by Mercer can:

the mugger
Order placed let's hope it's the start of regular ones
Hopefully next (in due course) EU OTC approval, then a takeover for a nice premium. 10-20p?
Price held strong at end is good sign.
FDA OTC is indeed a milestone..
Current mkt cap of 17m is paltry
Big pharma could well be tempted to take this out on the cheap.

Good news at last.
Hoping this is start of recovery.
Long term holders will be rewarded.

mam fach
Great volume since the US woke up...
This must now be on the radar of Big Pharma as a potential target for acquisition...
I tipped MXC yesterday
The cln has killed this dead dnt botht
Think this will soar when US markets open and UK brokers digest huge importence of OTC approval. Adding heavily at current low levels.
from russia with love
Certainly a step in right direction, otc status is a very significant development and highly desirable to any potential predator.
Heat ( sorry to cross thread ) but |I emailed Dave Horgan of CLON and posted his response on CLON CHAT LSE...he states all is on track with the JV in Bolivia Might well be worth a bob or two. In the meantime I am pleased with progress here at long last. Good luck with all you are doing.Ant
Hope your correct again Ant 👍🏻
And mxc has more drugs in the pipeline not just a one trick pony
Ps - I've printed of last DM and looking through it, sorry not been back but been hectic 🤦🤦

Chat Pages: Latest  689  688  687  686  685  684  683  682  681  680  679  678  Older
Your Recent History
Mgc Pharma..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20231004 16:20:10